At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 135 enrolled
Drug / intervention
AZD9833drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Open-Label, Parallel-Group, Pre-surgical Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2-negative Primary Breast Cancer (SERENA-3)
In Brief
A Phase 2 clinical trial evaluating AZD9833 for HER2-negative Breast Cancer. Completed, enrolled 135 participants across 12 sites in 3 countries.
Detailed Summary
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with primary breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-negative Breast Cancer
CountriesGeorgia, Mexico, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionJun 2023
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartNov 2, 2020
Primary CompletionJun 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.7 years ago
Interventions
AZD9833drug
AZD9833 tablets will be administered orally.